Evidence map›Paper›PMID 33861369›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2021

Outcomes of patients treated with a biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stents after rotational atherectomy.

Nader Mankerious, Rayyan Hemetsberger, Hussein Traboulsi, Ralph Toelg, Mohamed Abdel-Wahab, Gert Richardt, Abdelhakim Allali

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nader MankeriousHeart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel, Lübeck, and Hamburg, Am Kurpark 1, 23795, Bad Segeberg, Germany. nader.mankerious@gmail.com.ORCID http://orcid.org/0000-0003-4809-5371
Rayyan HemetsbergerHeart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel, Lübeck, and Hamburg, Am Kurpark 1, 23795, Bad Segeberg, Germany.
Hussein TraboulsiHeart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel, Lübeck, and Hamburg, Am Kurpark 1, 23795, Bad Segeberg, Germany.
Ralph ToelgHeart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel, Lübeck, and Hamburg, Am Kurpark 1, 23795, Bad Segeberg, Germany.
Mohamed Abdel-WahabCardiology Department, Heart Center Leipzig, University of Leipzig, Leipzig, Germany.
Gert RichardtHeart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel, Lübeck, and Hamburg, Am Kurpark 1, 23795, Bad Segeberg, Germany.
Abdelhakim AllaliHeart Center, Segeberger Kliniken GmbH, Academic Teaching Hospital of the Universities of Kiel, Lübeck, and Hamburg, Am Kurpark 1, 23795, Bad Segeberg, Germany.
Segeberger Kliniken · DELeipzig Heart Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare Orsiro biodegradable-polymer sirolimus-eluting stent (Orsiro BP-SES) with durable-polymer everolimus-eluting stent (DP-EES) regarding target lesion failure (TLF) after rotational atherectomy (RA), with a focus on small stents (diameter ≤ 3 mm) where Orsiro BP-SES has 60 µm strut thickness, while DP-EES remains with 81 µm strut thickness.

backgroundNew-generation drug-eluting stent (DES) is superior to early-generation DES in all percutaneous coronary intervention (PCI) settings including RA. Recently, the Orsiro BP-SES was superior to a DP-EES in an all comer's population.

methodsAmong patients who underwent RA at a single center, 121 were treated with Orsiro BP-SES and 164 with DP-EES (Promus and Xience). Those treated with other stent types, presenting with acute myocardial infarction or had a chronic total occlusion were excluded. Incidence of TLF was assessed.

resultsAfter 2 years, the TLF rate in Orsiro BP-SES and DP-EES groups was 10% and 18%, respectively (adjusted HR 0.55, 95%CI 0.26-1.16, p = 0.115). The rate of TLF was significantly lower in small Orsiro BP-SES with ultra-thin struts as compared to DP-EES with the same diameters (adjusted HR 0.19, 95% CI 0.04-0.87, p = 0.032), driven by lower rates of clinically driven target lesion revascularization (log-rank p = 0.022). Age (p = 0.035), total stent length (p = 0.007) and diabetes mellitus (p = 0.011) emerged as independent predictors of TLF in the whole population.

conclusionIn the whole cohort, Orsiro BP-SES and DP-EES had comparable rates of long-term TLF after RA. In the small stent subgroup, the Orsiro BP-SES with ultra-thin struts showed significant lower rate of TLF at 2 years.

Indexed as

Drug-Eluting StentsAbsorbable ImplantsAgedAtherectomy, CoronaryCoronary Artery DiseaseEverolimusFemaleFollow-Up StudiesHumansMalePolymersProsthesis DesignRetrospective StudiesSirolimusTreatment FailureTreatment OutcomeEverolimusPolymersSirolimusBiodegradable-polymerCoronary calcificationRotational atherectomyUltra-thin struts

Identifiers

PMID33861369
OpenAlexW3155542485

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.